<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996931</url>
  </required_header>
  <id_info>
    <org_study_id>RV-ASD-CHEZ-0329</org_study_id>
    <nct_id>NCT00996931</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders</brief_title>
  <official_title>A Phase II Pilot Study to Determine Efficacy and Safety of Lenalidomide (Revlimid) for Treatment of Autistic Spectrum Disorders(ASD) With Regression and Markers of Cerebrospinal Fluid Cytokine Elevation and Elevated TNF-alpha Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sutter Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sutter Medical Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if lenalidomide (Revlimid®)reduces proinflammatory
      cytokines including TNF-alpha and may actually alter the clinical course of autism for some
      children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autism currently affects 1:142 births and has no definite cause. Recent research has shown
      possible identifying markers in neuroglial inflammation with elevated cytokines IL-1, Il-6,
      and MCP-1 and elevated ratios of CSF/serum levels of TNF-alpha in patients with regressive
      autism.

      Lenalidomide (Revlimid®) is an analogue of thalidomide. Based on the improved clinical
      efficacy predicted for Revlimid® in its effects on TNF-alpha and other immunomodulatory
      cytokines, this oral compound may prove efficacious with less toxicity compared with
      thalidomide.

      The study will evaluate the efficacy of lenalidomide by measurement of changes in EEG,
      clinical global impression, Childhood Autism Rating Scale, and serum and CSF (if available)
      TNF-alpha at the end of the study compared with the same measurements at baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TNF-alpha Levels</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in CSF-TNF-α from baseline to 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Childhood Autism Rating Scale (CARS)Value From Baseline to 6 Weeks</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Change in CARS value from baseline to 6 weeks. Total CARS scores range from a fifteen to 60, with a minimum score of thirty serving as the cutoff for a diagnosis of autism on the mild end of the autism spectrum.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>2.5 mgs per day orally for 12 weeks</description>
    <arm_group_label>Lenalidomide</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of autistic spectrum disorder as defined by DSM-IV criteria.

          -  Inflammatory CSF and serum markers with elevated level of TNF-Alfa (&gt; 50pg/ml) or
             other Cytokine markers such as IL-1, IL-6 or MECP-1, or serum levels of such cytokines
             greater than 2X normal levels even in absence of CSF markers.

        or

          -  Patients with interictal epiliptiform EEG changes in the absences of clinical
             seizures, if CSF inflammatory markers are identified.

          -  Patients will maintain any other baseline medications for autistic problems or EEG
             treatment as long as on these for prior 6-8 weeks with no dosage changes. Mentally
             impaired minors require a parent or legal guardian to sign the informed consent.

        Exclusion Criteria:

          -  -Diagnosis of PPD-NOS and other autism spectrum disorders.

          -  Any serious medical condition, laboratory abnormality, genetic, brain, structural, or
             psychiatric illness that would prevent the subject from participating.

          -  History of neutropenia, thrombocytopenia or other types of myelosuppression or risk
             factors for myelosuppression.

          -  History or risk factors for thromboembolic events.

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          -  Use of any other experimental drug or therapy within 28 days of baseline.

          -  Current use of steroids (e.g. dexamethasone, prednisone), anthracyclines (Doxil,
             Adriamycin).

          -  Known hypersensitivity to thalidomide.

          -  The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

          -  Any prior use of lenalidomide.

          -  Known positive for HIV or infectious hepatitis, type A, B or C or tuberculosis.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Chez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sutter Medical Foundation</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <results_first_submitted>August 30, 2011</results_first_submitted>
  <results_first_submitted_qc>April 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2013</results_first_posted>
  <last_update_submitted>April 24, 2013</last_update_submitted>
  <last_update_submitted_qc>April 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sutter Medical Foundation</investigator_affiliation>
    <investigator_full_name>Michael G. Chez, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>autistic spectrum disorder</keyword>
  <keyword>lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide</title>
          <description>Six patients will receive oral 2.5 mg daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide</title>
          <description>Six patients will receive 2.5 mg oral daily for 12 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in TNF-alpha Levels</title>
        <description>Change in CSF-TNF-α from baseline to 12 weeks.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Six subjects received oral 2.5 mg daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TNF-alpha Levels</title>
          <description>Change in CSF-TNF-α from baseline to 12 weeks.</description>
          <population>Intention to treat</population>
          <units>mean % change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Childhood Autism Rating Scale (CARS)Value From Baseline to 6 Weeks</title>
        <description>Change in CARS value from baseline to 6 weeks. Total CARS scores range from a fifteen to 60, with a minimum score of thirty serving as the cutoff for a diagnosis of autism on the mild end of the autism spectrum.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>oral 25 mg daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Childhood Autism Rating Scale (CARS)Value From Baseline to 6 Weeks</title>
          <description>Change in CARS value from baseline to 6 weeks. Total CARS scores range from a fifteen to 60, with a minimum score of thirty serving as the cutoff for a diagnosis of autism on the mild end of the autism spectrum.</description>
          <population>Intention to treat</population>
          <units>mean change in units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide</title>
          <description>Six patients will receive 2.5 mg oral daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carol Parise, PhD</name_or_title>
      <organization>Sutter Institute for Medical Research</organization>
      <phone>916-733-4413</phone>
      <email>PariseC@sutterhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

